People

Center Executive Committee and Project Leaders

Peter Sorger, PhD
Otto Krayer Professor of Systems Biology, Harvard Medical School
Founding Director of the Laboratory of Systems Pharmacology
Head of the Harvard Program in Therapeutic Science
Principal Investigator, Member CCSP Executive Committee, and Head of Project 1

Peter Sorger leads the CCSP and the shared research laboratory in which much of the work is based (the Lab of Systems Pharmacology). The Sorger lab focuses on the systems biology of mammalian signal transduction and uses single-cell and multiplexed imaging and mass spectrometry methods to constrain and validate physico-chemical models of oncogenesis and drug action. As part of the CSSP, Sorger and his group are investigating the molecular analysis of adaptive drug resistance (Project 1) and using multiplex methods to study the tumor microenvironment (Project 2).

Marcia Haigis, PhD
Professor in Cell Biology, Harvard Medical School
Member CCSP Executive Committee and Co-Head of Project 3

Marcia Haigis studies the metabolic programs of mammalian cells and the pathways that regulate these programs. She focuses on metabolic reprogramming of tumor cells and immune cells within the tumor microenvironment to discover novel anti-tumor therapies. As part of the CCSP, Haigis and her group investigate the mechanisms of response and resistance to immune checkpoint inhibitors (Project 3) and lead the metabolomics efforts in the Systems Pharmacology core.

Sandro Santagata, MD, PhD
Associate Pathologist in Neuropathology, Brigham and Women’s Hospital
Assistant Professor in Pathology, Harvard Medical School
Member CCSP Executive Committee and Head of Project 2

Sandro Santagata is a Neuropathologist in the Department of Pathology at Brigham and Women’s Hospital and in the Department of Oncologic Pathology at Dana-Farber Cancer Institute. He applies novel tissue imaging methods, including tissue-based cyclic immunofluorescence (t-CyCIF), to characterize brain tumors. Using clinical trial specimens, he measures and models therapeutic responses in tumors and their microenvironment (Project 2).

Artem Sokolov, PhD
Instructor in Biomedical Informatics, Harvard Medical School
Head of Modeling and Informatics Platform, Harvard Program in Therapeutic Science
Member CCSP Executive Committee and Systems Pharmacology Core Lead

Artem Sokolov has an extensive background in machine learning and its application to molecular and clinical datasets. As part of the CCSP, he leads a team of scientists who are actively developing and maintaining computational pipelines for analyzing transcriptomics, proteomics, and imaging data collected for Projects 1-3. Sokolov is actively involved in the CSBC and co-chairs the CSBC/PS-ON Image Analysis Working Group, which is focused on systematic development and evaluation of methods for cell segmentation in high-dimensional biomedical images.

Hanspeter Pfister, PhD
An Wang Professor of Computer Science
Harvard John A. Paulson School of Engineering and Applied Sciences
Member CCSP Executive Committee

Hanspeter Pfister’s research in visual computing lies at the intersection of visualization, computer graphics, and computer vision and spans a wide range of topics, including biomedical image analysis and visualization, image and video analysis, interpretable machine learning, and visual analytics in data science. Pfister was recruited through our year 1 pilot project on machine-vision approaches to tissue analysis. He and his lab are developing machine learning methods for analyzing multi-dimensional tumor tissue images with the goal of more accurately assigning cell type and determining the distribution of tumor, stromal, and immune cells in cancers before and after treatment (Project 2).

Jennifer Guerriero, PhD
Director of the Breast Immunology Laboratory, Dana-Farber Cancer Institute
Instructor in Medicine, Harvard Medical School
Member CCSP Executive Committee

Jennifer Guerriero studies the role of tumor associated macrophages in promoting tumorigenesis and as a therapeutic target. Her research aims to understand the molecular and functional regulation of tumor macrophage phenotype and subsets, identify how tumor macrophages inhibit T cell function and limit the effectiveness of immunotherapy, and identify novel strategies to target macrophages therapeutically. Guerriero was recruited through outreach by the Systems Pharmacology Core and has brought new insight into macrophage biology to the CCSP, particularly in the context of breast cancer and immune therapy (Project 3).

Luca Gerosa, PhD
Postdoctoral Fellow, Sorger Lab, Harvard Medical School
Member CCSP Executive Committee

Luca Gerosa is a postdoctoral fellow in the CCSP who serves on the Executive Committee as a representative of the trainees. He helps to organize the monthly super-group meetings and annual retreat. Gerosa is an expert in computational and experimental systems biology working on adaptive drug resistance in BRAF mutant cancers (Project 1).

Alyce Chen, PhD, MPH
Scientific Program Manager, Harvard Program in Therapeutic Science
Member CCSP Executive Committee, Ex Officio and Education and Outreach Lead

Alyce Chen is a scientific program manager for the Harvard Program in Therapeutic Science and the Laboratory of Systems Pharmacology. She ensures the smooth operation of the Center’s communication infrastructure, monitors progress on all time lines, and assists the PIs in reporting progress to the NCI. She serves as the Center Administrator and the lead of the Education and Outreach Core for CCSP.

Center Faculty and Investigators

Arlene Sharpe, MD, PhD
George Fabyan Professor of Comparative Pathology
Chair, Department of Immunology, Harvard Medical School
Co-Director of the Evergrande Center for Immunologic Diseases
Co-Head of Project 3

Arlene Sharpe studies T-cell costimulation and its immunoregulatory functions in T cell tolerance and anti-tumor immunity. Her laboratory has been at the forefront of this field for over two decades, discovering T cell costimulatory pathways and elucidating their functions, including the functions of B7-1 and B7-2, CTLA-4, ICOS, PD-1, and PD-1 ligands.

Mohammed AlQuraishi, PhD
Independent Fellow in Therapeutic Science
Laboratory of Systems Pharmacology

Mohammed AlQuraishi works at the intersection between computer science, systems biology, and structural biology. He develops bespoke machine learning models that use biophysical insight to learn protein structure from primary sequence via differentiable algorithms, of which deep learning is a specific example. Biological applications include ab initio structure prediction, modeling signal transduction networks and protein-small molecule docking.

Genevieve Boland, MD, PhD
Director, Melanoma Surgery Program, Massachusetts General Hospital
Director, Surgical Oncology Research Laboratories, Massachusetts General Hospital
Assistant Professor, Harvard Medical School

Genevieve Boland is focused on the identification of tumor-intrinsic and immune-related mechanisms of response and resistance to immunotherapy and the identification of blood-based biomarkers of therapeutic response. Her laboratory is also defining and characterizing biomarkers of immune-related toxicities to develop new clinical targets and diagnostic tools.

Conor Evans, PhD
Associate Professor, Harvard Medical School
Wellman Center for Photomedicine, Massachusetts General Hospital

Conor Evans and his team develop optical technologies targeting challenges in clinical and pre-clinical medicine. As part of the CCSP, Dr. Evans and his team are creating advanced imaging technologies for the direct visualization and quantification of pharmacokinetics and pharmacodynamics in situ. By leveraging tools such as coherent Raman imaging, image analysis, and machine learning, his group aims to improve our understanding of how cancer drugs reach and engage their targets.

Keith Flaherty, MD
Director of Clinical Research, Massachusetts General Hospital
Professor of Medicine at Harvard Medical School

Keith Flaherty focuses on understanding mechanisms of action and resistance to signal transduction targeted therapy and immunotherapy in melanoma as well as the mechanistic interaction between the two modalities. Deep molecular analysis of serial tumor biopsies and rapid autopsy samples are used to motivate functional pre-clinical studies and to inform next generation clinical trials.

Benjamin Izar, MD, PhD
Assistant Professor at Columbia University Medical Center (CUMC)
Center for Translational Tumor Immunology (CCTI)
Program for Mathematical Genomics at Columbia University

Benjamin Izar has pioneered the implementation of single-cell RNA-sequencing and single-cell protein imaging in clinical specimens and the development of patient-derived models to understand drug resistance to targeted therapies and immune checkpoint inhibitors. As a medical oncologist, he focuses on the treatment and understanding of drug resistance in melanoma.

Nicole LeBoeuf, MD, MPH
Clinical Director, Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center
Director, The Program in Skin Toxicities from Anticancer Therapies
Assistant Professor of Dermatology, Harvard Medical School

Nicole LeBoeuf provides urgent and ongoing expert dermatologic care for cancer patients with cutaneous adverse events from oncologic treatments. Her research focuses on profiling the immune infiltrate in the skin and blood of patients with cutaneous eruptions from immune checkpoint blockade.

Key Collaborators

Sameer Chopra, MD, PhD
Associate Medical Director, Translational Sciences/Drug Development Unit, Takeda Oncology

Sameer Chopra is interested in the relationship between genome instability and anti-tumor immunity in triple-negative breast cancer and high grade serous ovarian cancer. His goal is to apply systems pharmacology approaches to develop curative therapeutic strategies for women’s cancers using combinations of small molecule drugs and immunotherapy.

F. Stephen Hodi, MD
Director of the Melanoma Center and the Center for Immuno-Oncology
Institute Physician, Dana-Farber Cancer Institute
Sharon Crowley Martin Chair in Melanoma
Professor of Medicine, Harvard Medical School

Stephen Hodi studies mechanisms of immuno-therapy via clinical trials in multiple disease areas. He focuses on understanding determinants of response and the specific disease features that allow a subset of patients to experience extremely durable responses to immune checkpoint inhibition.

Douglas Lauffenburger, PhD
Ford Professor of Bioengineering
Professor of Biological Engineering, Chemical Engineering, and Biology, Massachusetts Institute of Technology

Douglas Lauffenburger studies cell dysregulation in complex pathophysiologies, emphasizing applications in cancer, inflammatory diseases, and vaccines. A central objective is gaining understanding of how multiple pathways and processes — both intracellular and intercellular – combine to govern cell functions and how they become dysregulated in disease.

Patrick Ott, MD, PhD
Clinical Director, Center for Immuno-Oncology and Melanoma Center, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School

Patrick Ott is interested in the development of new immunotherapeutic strategies for cancer patients. He is the principal investigator and site investigator of a large portfolio of clinical trials assessing novel agents and innovative combinatorial strategies for patients with melanoma and other cancers.